$59.77
2.08% yesterday
Nasdaq, Dec 03, 10:00 pm CET

Lantheus Holdings Inc Stock price

$59.77
+2.95 5.19% 1M
-17.92 23.07% 6M
-29.69 33.19% YTD
-28.74 32.47% 1Y
+3.76 6.71% 3Y
+46.37 346.04% 5Y
+55.95 1,464.66% 10Y
+53.00 782.87% 20Y
Nasdaq, Closing price Wed, Dec 03 2025
+1.22 2.08%

New AI Insights on Lantheus Holdings Inc Insights AI Insights on Lantheus Holdings Inc

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?
How is the company managed?

Key metrics

Basic
Market capitalization
$4.0b
Enterprise Value
$4.2b
Net debt
$186.8m
Cash
$382.0m
Shares outstanding
66.3m
Valuation (TTM | estimate)
P/E
24.2 | 10.4
P/S
2.6 | 2.6
EV/Sales
2.7 | 2.7
EV/FCF
10.0
P/B
3.5
Financial Health
Equity Ratio
54.9%
Return on Equity
28.7%
ROCE
17.9%
ROIC
13.4%
Debt/Equity
0.5
Financials (TTM | estimate)
Revenue
$1.5b | $1.5b
EBITDA
$409.9m | $569.8m
EBIT
$345.4m | $552.3m
Net Income
$167.7m | $380.6m
Free Cash Flow
$414.0m
Growth (TTM | estimate)
Revenue
2.0% | -1.4%
EBITDA
-23.6% | 11.0%
EBIT
-27.2% | 23.1%
Net Income
-60.8% | 21.8%
Free Cash Flow
9.4%
Margin (TTM | estimate)
Gross
62.2%
EBITDA
26.9% | 37.7%
EBIT
22.6%
Net
11.0% | 25.2%
Free Cash Flow
27.1%
More
EPS
$2.5
FCF per Share
$6.2
Short interest
14.3%
Employees
808
Rev per Employee
$1.9m
Show more

Is Lantheus Holdings Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,088 stocks worldwide.

Lantheus Holdings Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

19 Analysts have issued a Lantheus Holdings Inc forecast:

15x Buy
79%
4x Hold
21%

Analyst Opinions

19 Analysts have issued a Lantheus Holdings Inc forecast:

Buy
79%
Hold
21%

Financial data from Lantheus Holdings Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
1,526 1,526
2% 2%
100%
- Direct Costs 576 576
9% 9%
38%
950 950
2% 2%
62%
- Selling and Administrative Expenses 439 439
27% 27%
29%
- Research and Development Expense 165 165
10% 10%
11%
410 410
24% 24%
27%
- Depreciation and Amortization 65 65
3% 3%
4%
EBIT (Operating Income) EBIT 345 345
27% 27%
23%
Net Profit 168 168
61% 61%
11%

In millions USD.

Don't miss a Thing! We will send you all news about Lantheus Holdings Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Lantheus Holdings Inc Stock News

Positive
Seeking Alpha
21 days ago
Lantheus Holdings offers compelling value as a leading cancer diagnostic and treatment company, with a robust drug pipeline and defensive business model. LNTH shares have dropped nearly 60% since March due to weaker sales, product pricing issues, and rising costs, compressing margins in 2025. Despite recent challenges (or because of), Lantheus trades at a historically low valuation, with analys...
Neutral
Seeking Alpha
21 days ago
Small-cap stocks extended their momentum into the third quarter. We believe Rambus' evolution from a licensing and patent company into a full-fledged product company is progressing well. Shake Shack stock pulled back following quarterly results that did not meet elevated expectations.
Neutral
PRNewsWire
26 days ago
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Lantheus To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Lantheus between February 26, 2025 and August 5, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 ...
More Lantheus Holdings Inc News

Company Profile

Lantheus Holdings, Inc. engages in the development, manufacture and commercialization of diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. Its products are used by cardiologists, nuclear physicians, radiologists, internal medicine physicians, sonographers and technologists working in a variety of clinical settings. The firm operates through the following geographical segments: U.S. and International. The U.S. segment produces and markets medical imaging agents and products throughout the U.S. This segment sells its products to radio pharmacies, integrated delivery networks, hospitals, clinics and group practices. The International segment operations consist of production and distribution activities in Puerto Rico and direct distribution activities in Canada. The company was founded in 1956 and is headquartered in North Billerica, MA.

Head office United States
CEO Brian Markison
Employees 808
Founded 1956
Website www.lantheus.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today